Please wait while the formulary information is being retrieved.
MITOMYCIN (MITOMYCIN)
- Adenocarcinoma of pancreas
- Metastatic gastric cancer
20 mg intravenous solution
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
40 mg intravenous solution
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
5 mg intravenous solution
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
20 mg intravenous solution
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
40 mg intravenous solution
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
5 mg intravenous solution
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
20 mg intravenous solution
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
40 mg intravenous solution
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
5 mg intravenous solution
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
Adenocarcinoma of pancreas
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
- Inject 20 mg/m2 by intravenous route every 6 weeks
- Inject 20 mg/m2 by intravenous route every 8 weeks
- Inject 10 mg/m2 by intravenous route once
Localized malignant tumor of anus
- Inject 10 mg/m2 by intravenous route on days 1 and 29 (not to exceed 20 mg/dose)
Malignant tumor of urinary bladder
- Instill 40 mg by intravesical route ;Retain in bladder for 2 hours
- Instill 20 mg by intravesical route once weekly for 6 weeks , then 20Mg every month for 3 years ;Retain in bladder for 1-2 hours
Metastatic gastric cancer
- Inject 20 mg/m2 by intravenous route every 6 - 8 weeks
- Inject 20 mg/m2 by intravenous route every 6 weeks
- Inject 20 mg/m2 by intravenous route every 8 weeks
- Inject 10 mg/m2 by intravenous route once
Prevention of recurrent bladder carcinoma
- Instill 40 mg by intravesical route ;Retain in bladder for 2 hours
- Instill 20 mg by intravesical route once weekly for 6 weeks , then 20Mg every month for 3 years ;Retain in bladder for 1-2 hours
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Increased risk of bleeding
- Increased risk of bleeding due to coagulation disorder
- Lactating mother
- Pregnancy
- Severe infection
- Thrombocytopenic disorder
Contraindicated
- Anemia
- Bone marrow depression
- Heart failure
- Hemolytic uremic syndrome
- Kidney disease with reduction in GFR
- Leukopenia
- Pulmonary infiltrates
- Stomatitis
Severe
Moderate
- None
MITOMYCIN (MITOMYCIN)
- Adenocarcinoma of pancreas
- Metastatic gastric cancer
- Bone marrow depression
- Infection
- Leukopenia
- Thrombocytopenic disorder
- Anorexia
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Neutropenic disorder
- Pulmonary disease
- Renal failure
- Stomatitis
- Alopecia
- Fatigue
- General weakness
- Nail discoloration
- Skin rash
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Bloody vomit
- Hemolytic uremic syndrome
- Injection site sequelae
- Thrombophlebitis
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Mitomycin
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Mitomycin
- Severity Level:
X
- Additional Notes: Parenteral administration teratogenic in animals at therapeutic doses
Contraindicated
Mitomycin
Potential severe toxicity; consider holding breastfeeding after treatment
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Potential severe toxicity; consider holding breastfeeding after treatment |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Mitomycin
Renal-Fluid retention risk. Carefully monitor fluid balance in patients with renal impairment. Cardiovascular-Use caution in heart failure patients.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Mitomycin may cause serious blood and bone marrow disorders (e.g., low red blood cells/white blood cells/platelets). These problems can affect your body's ability to stop bleeding or fight infection. Tell your doctor right away if you develop easy bleeding/bruising or signs of an infection (e.g., fever, chills, persistent sore throat).<br /><br /> This drug may cause a certain serious, sometimes fatal side effect (hemolytic uremic syndrome). This condition may result in anemia, low platelet counts, and kidney problems. Blood transfusions may make the symptoms worse. Tell your doctor right away if you have any of the following signs: pink/bloody urine or change in the amount of urine.
| Adenocarcinoma of pancreas | |
| C24.1 | Malignant neoplasm of ampulla of vater |
| C25 | Malignant neoplasm of pancreas |
| C25.0 | Malignant neoplasm of head of pancreas |
| C25.1 | Malignant neoplasm of body of pancreas |
| C25.2 | Malignant neoplasm of tail of pancreas |
| C25.3 | Malignant neoplasm of pancreatic duct |
| C25.4 | Malignant neoplasm of endocrine pancreas |
| C25.7 | Malignant neoplasm of other parts of pancreas |
| C25.8 | Malignant neoplasm of overlapping sites of pancreas |
| C25.9 | Malignant neoplasm of pancreas, unspecified |
| Metastatic gastric cancer | |
| C16 | Malignant neoplasm of stomach |
| C16.0 | Malignant neoplasm of cardia |
| C16.1 | Malignant neoplasm of fundus of stomach |
| C16.2 | Malignant neoplasm of body of stomach |
| C16.3 | Malignant neoplasm of pyloric antrum |
| C16.4 | Malignant neoplasm of pylorus |
| C16.5 | Malignant neoplasm of lesser curvature of stomach, unspecified |
| C16.6 | Malignant neoplasm of greater curvature of stomach, unspecified |
| C16.8 | Malignant neoplasm of overlapping sites of stomach |
| C16.9 | Malignant neoplasm of stomach, unspecified |
| 0-9 | A-Z |
|---|---|
| C16 | Malignant neoplasm of stomach |
| C16.0 | Malignant neoplasm of cardia |
| C16.1 | Malignant neoplasm of fundus of stomach |
| C16.2 | Malignant neoplasm of body of stomach |
| C16.3 | Malignant neoplasm of pyloric antrum |
| C16.4 | Malignant neoplasm of pylorus |
| C16.5 | Malignant neoplasm of lesser curvature of stomach, unspecified |
| C16.6 | Malignant neoplasm of greater curvature of stomach, unspecified |
| C16.8 | Malignant neoplasm of overlapping sites of stomach |
| C16.9 | Malignant neoplasm of stomach, unspecified |
| C24.1 | Malignant neoplasm of ampulla of vater |
| C25 | Malignant neoplasm of pancreas |
| C25.0 | Malignant neoplasm of head of pancreas |
| C25.1 | Malignant neoplasm of body of pancreas |
| C25.2 | Malignant neoplasm of tail of pancreas |
| C25.3 | Malignant neoplasm of pancreatic duct |
| C25.4 | Malignant neoplasm of endocrine pancreas |
| C25.7 | Malignant neoplasm of other parts of pancreas |
| C25.8 | Malignant neoplasm of overlapping sites of pancreas |
| C25.9 | Malignant neoplasm of pancreas, unspecified |
Formulary Reference Tool